Related Experiment Videos

Mortality and morbidity of newly diagnosed heart failure treated with statins: a propensity-adjusted cohort study

Francisco M Gomez-Soto1, Sotero P Romero, Jose A Bernal

  • 1Department of Medicine, Hospital Universitario Puerto Real, University of Cadiz, School of Medicine, Spain. francisco.gomez@uca.es

International Journal of Cardiology
|December 25, 2008
PubMed

Insights

Starting statin therapy significantly lowers mortality and hospitalization rates in patients with newly diagnosed heart failure (ndHF). This benefit is dose-dependent, improving outcomes for both systolic and non-systolic heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The impact of statin therapy on the prognosis of newly diagnosed heart failure (ndHF) remains unclear.
  • Statins are widely prescribed for cardiovascular disease prevention, but their role in established heart failure is less defined.

Purpose of the Study:

  • To investigate the association between commencing statin treatment (CTS) and the mortality and morbidity in patients with newly diagnosed heart failure.
  • To analyze these associations separately for systolic (HF-DSF) and non-systolic (HF-PSF) heart failure.

Main Methods:

  • A 5-year prospective, propensity-adjusted cohort study involving 2573 patients with ndHF.
  • Outcomes included all-cause and cardiovascular mortality, and hospitalization rates.
  • Analyses were adjusted for confounders and stratified by cardiovascular comorbidity.

Main Results:

  • Commencing statin treatment (52.2% of patients) was linked to significantly reduced mortality (RR 0.23) and hospitalization rates across all ndHF types.
  • A dose-dependent relationship was observed, with higher statin doses (>20 mg/day) showing greater risk reduction.
  • These benefits persisted after adjusting for confounding factors and propensity to receive statins.

Conclusions:

  • Commencing statin treatment is associated with a dose-dependent reduction in mortality and morbidity for patients with newly diagnosed heart failure.
  • Statin therapy appears to be a beneficial intervention for improving outcomes in ndHF patients, regardless of ejection fraction.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...